Daewoong Pharmaceutical announced on July 31st that its botulinum toxin product "Nabota" achieved sales of 115.4 billion KRW in the first half of the year. This represents an approximately 28% increase compared to 90.2 billion KRW during the same period last year, placing the company on track to potentially surpass 200 billion KRW in annual sales for the year.
Nabota made significant strides into the global market after becoming the first Asian botulinum toxin to receive FDA approval in 2019. The U.S., being the largest market for botulinum toxin globally, has rigorous standards for quality, safety, and manufacturing management, making Nabota's success there particularly notable.
The company is strengthening its position in the global market as a “premium toxin” through high-purity and high-quality strategies, alongside enhanced educational and academic programs for healthcare professionals.
Nabota has shown consistent growth across major global markets. It has captured 14% of the cosmetic toxin market in the U.S. under the brand name "Jeuveau," securing the second-largest market share. In South America and Southeast Asia, Nabota has made remarkable progresses; a significant export contract worth 180 billion KRW, ten times its original 2018 contract, was secured in Brazil. In Thailand, a renewed contract valued at 73.8 billion KRW—three times the previous amount—was successfully established.
Recently, Daewoong secured an export contract with Kuwait, allowing Nabota to supply to five Middle Eastern countries. This positions Daewoong as the domestic toxin company with the broadest reach in the Gulf region, having expanded its presence to high-demand markets including UAE, Saudi Arabia, and Qatar. The growth in the Middle Eastern market is expected to accelerate further.
In the latter half of the year, Daewoong plans to increase its market share in existing countries and actively pursue entry into new markets, reinforcing its position globally with a focus on high-purity and high-quality premium strategies.
Nabota is pioneering the "K-Medical Aesthetic" trend with its proprietary "NaborLift" procedure and integrated treatment education programs. Daewoong Pharmaceutical is focusing not only on marketing but also on improving the procedural capabilities of local medical professionals and enhancing patient satisfaction. The company aims to establish a successful "Win-Win-Win" model benefiting medical professionals, patients, and the company itself.
To further strengthen its scientific backing, Daewoong continuously engages in academic activities such as global conferences, webinars, and training programs, while expanding collaborations in clinical research with local medical professionals.
Junsu Yoon, head of Daewoong Pharmaceutical’s Nabota Business Division, stated, “Nabota has now established itself as a leading top-tier brand in the global market. We aim to enhance our competitiveness in key markets based on high purity and quality, and to become a leader in the global medical aesthetics field.”
